Additive Effects of Simvastatin and Ramipril on Inflammatory Cytokines Interferon-γ, Tumor Necrosis Factor-α, Interleukin-6 and C-Reactive Protein in Diabetic Patients with Congestive Heart Failure

Synergistic effects of pravastatin and pioglitazone in renal tubular epithelial cells induced by transforming growth factor‐β1

“…Data from several sources suggested that simple strategies combining PPAR-g agonist and statins could have complementary effects on cardiovascular disease risk factors profiles in diabetes, alongside the ability to control glycaemia (Erdmann, 2005). Recently presented data indicated that pioglitazone and simvastatin might act synergistically to decrease the levels of inflammatory cytokines, including interleukin-6 and C-reactive protein, as well as optimizing patients' lipid profiles (Tan and Tan, 2004). Recently presented data indicated that pioglitazone and simvastatin might act synergistically to decrease the levels of inflammatory cytokines, including interleukin-6 and C-reactive protein, as well as optimizing patients' lipid profiles (Tan and Tan, 2004).…”

“…According to our results, treatment with pravastatin plus pioglitazone further inhibited the expression of a-SMA, CTGF, FN, PAI-1 and collagen 1 in HK-2 cells induced by TGF-b1. Recently presented data indicated that pioglitazone and simvastatin might act synergistically to decrease the levels of inflammatory cytokines, including interleukin-6 and C-reactive protein, as well as optimizing patients' lipid profiles (Tan and Tan, 2004). Chen and Mehta (2006) reported that the inhibitory effects on collagen-1 synthesis in cardiac fibroblast stimulated by Angiotensin II was related to the antioxidant effects of pioglitazone and pravastatin.…”

Differences in Expression of Cardiovascular Risk Factors among Type 2 Diabetes Mellitus Patients of Different Age

“…When a metabolic pathway of homocysteine is inhibited, then homocysteine accumulates causing increased levels of homocysteine in plasma. Several studies have indicated that even moderately elevated plasma homocysteine is a predictor of CVD 48 . The risk of either stroke or CHD is 1.5–3 times higher, when the levels of plasma homocysteine are moderately elevated 49 .…”

“…Several studies have indicated that even moderately elevated plasma homocysteine is a predictor of CVD. 48 The risk of either stroke or CHD is 1.5-3 times higher, when the levels of plasma homocysteine are moderately elevated. 49 During the acute phase of myocardial infarction, an increase in homocysteine occurs, which may be connected with the increase of acute phase proteins.…”